ASH 2011 Conference Coverage

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

Whole-exome sequencing of tumor biopsies explain low response rate to immunotherapy in metastatic melanoma.

Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk

Predictive risk model shows that lifestyle choices have a greater influence on risk for colorectal cancer than does genetic factors.

Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer

Patients with metastatic kidney cancer may also have an primary lung cancer that has gone gone undiagnosed.

Nasal Biomarker in Smokers Could Predict Lung Cancer

Novel diagnostic test determines whether suspicious lung lesions or nodules are malignant disease from a sample obtained via nasal swab.

Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer

[OncoTargets and Therapy] This research examines the lymphatic flow in the arm following breast cancer surgery and axillary lymph node dissection (ALND) versus sentinel lymph node biopsy (SLNB) using lymphoscintigraphy (LS).

Fluciclovine PET/CT Improves Targeted Radiation Treatment of Recurrent Prostate Cancer

F-18-fluciclovine PET helps detect and localize recurrent prostate cancer allowing for individualized, targeted therapy.

Single Fraction of HDR Brachytherapy Found Effective in Localized Prostate Cancer

A single 19-Gy fraction of brachytherapy was found as effective as a longer regimen of low-dose-rate brachytherapy in localized prostate cancer.

Everolimus Found to Improve Chemotherapy-Induced Infertility in Preclinical Research

A study using a mouse model to investigate the effect of adding everolimus to cyclophosphamide to slow tumor growth found the drug also preserves fertility.

Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results

A significantly shorter course of trastuzumab achieved both improved outcomes for patients and cost savings for the UK National Health Service.

Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer

Cabozantinib activated innate immunity and completely eradicated prostate cancer in a study using a mouse model.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs